NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Picot J, Cooper K, Bryant J, et al. The Clinical Effectiveness and Cost-Effectiveness of Bortezomib and Thalidomide in Combination Regimens with an Alkylating Agent and a Corticosteroid for the First-Line Treatment of Multiple Myeloma: A Systematic Review and Economic Evaluation. Southampton (UK): NIHR Journals Library; 2011 Dec. (Health Technology Assessment, No. 15.41.)

Cover of The Clinical Effectiveness and Cost-Effectiveness of Bortezomib and Thalidomide in Combination Regimens with an Alkylating Agent and a Corticosteroid for the First-Line Treatment of Multiple Myeloma: A Systematic Review and Economic Evaluation

The Clinical Effectiveness and Cost-Effectiveness of Bortezomib and Thalidomide in Combination Regimens with an Alkylating Agent and a Corticosteroid for the First-Line Treatment of Multiple Myeloma: A Systematic Review and Economic Evaluation.

Show details

Appendix 12Critical appraisal checklist of economic evaluation

The quality of the cost-effectiveness studies was assessed using a critical appraisal checklist based on that by Drummond and Jefferson,118 Philips and colleagues,98 and the NICE reference case.

ItemCelgene116Janssen–Cilag115
1Is there a clear statement of the decision problem?YY
2Is the comparator routinely used in UK NHS?YY
3Is the patient group in the study similar to those of interest in UK NHS??Y
4Is the health-care system or setting comparable to UK?YY
5Is the perspective of the model clearly stated?YY
6Is the study type and modelling methodology reasonable?YY
7Is the model structure described and does it reflect the disease process??Y
8Are assumptions about model structure listed and justified?YY
9Are the data inputs for the model described and justified?YY
10Is the effectiveness of the intervention established based on a systematic review?YY
11Are health benefits measured in QALYs?YY
12Are health benefits measured using a standardised and validated generic instrument?YY
13Are the resource costs described and justified?YY
14Have the costs and outcomes been discounted?YY
15Has uncertainty been assessed?YY
16Has the model been validated?NN

Y, yes; N, no; ?, unclear/incomplete.

© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

Bookshelf ID: NBK97483

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.5M)

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...